Guggenheim Capital’s Cogent Biosciences COGT Stock Holding History

Guggenheim Capital’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.49M	Buy	+38,755	New	+$1.43M	0.01%	820

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Guggenheim Capital's COGT Position: Q1 2026 in Review

Guggenheim Capital opened a new position in Cogent Biosciences (COGT) in Q1 2026: 38,755 shares worth $1.49M. The stake represents 0.01% of the portfolio and ranks #820 among its holdings.

305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

Guggenheim Capital held 38,755 shares of Cogent Biosciences worth $1.49M as of Q1 2026.
Cogent Biosciences was a new Guggenheim Capital position in Q1 2026.
Cogent Biosciences made up 0.01% of Guggenheim Capital's portfolio in Q1 2026, its #820 holding.
305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.